Search the Newsreel

GNTX Maintained by JP Morgan -- Price Target Lowered to $27.00

JP Morgan analyst Rajat Gupta maintained a neutral rating for Gentex (GNTX) but lowered its price target to $27.00 from $28.00. Despite this, GuruFocus assesses GNTX as undervalued by 28.8% with a strong GF Score of 92/100, driven by excellent financial strength and profitability. …

Texas Instruments Inc. stock outperforms competitors despite losses on the day

Shares of Texas Instruments Inc. fell by 1.97% to $280.44 on Monday, despite the stock outperforming competitors. The decline occurred during a tough trading session where both the S&P 500 Index and Dow Jones Industrial Average also saw losses. This drop ended a two-day …

Textron Aviation files plans for $24.5M in renovations to Wichita campuses

Textron Aviation is investing $24.5 million in renovations across its Wichita manufacturing campuses, including a $16 million corridor reconstruction project. The company, which employs 11,000 workers locally, is undertaking these upgrades as part of its ongoing commitment to its facilities.

JPMorgan Chase & Co. Lowers Gentex (NASDAQ:GNTX) Price Target to $27.00

JPMorgan Chase & Co. has reduced its price target for Gentex (NASDAQ:GNTX) to $27.00 from $28.00, while maintaining a "neutral" rating. This new target implies a potential upside of 13.23% from the stock's previous close. Despite beating EPS expectations with $0.58, Gentex's revenue of …

Horizon Kinetics Asset Management buys $353 in Texas Pacific Land shares

Horizon Kinetics Asset Management LLC, a significant shareholder in Texas Pacific Land Corp (TPL), recently purchased additional shares worth $353 at $353.28 each. This transaction occurred after TPL's stock had declined by 16% over the past week and is trading significantly below its 52-week …

Nutex Health jumps 21%, continuing post-earnings run (NUTX:NASDAQ)

Nutex Health (NUTX) shares surged nearly 21% on Monday, extending a previous 7% gain after the company's second-quarter earnings release. The stock's recent performance is attributed to strong Q2 earnings, significant net income improvement, and cost reductions, despite a revenue miss. The company's earnings …

Texas Pacific Land Corp (TPL) major holder logs small open-market share purchase

Horizon Kinetics Asset Management LLC, a significant holder of Texas Pacific Land Corp (TPL), reported a small open-market purchase of 1 common stock share at $353.28 on August 7, 2026. This transaction brings its direct holdings to 3,244,005 shares. A footnote clarifies that the …

TEXAS ROADHOUSE INC : PIPER SANDLER RAISES TARGET PRICE TO $208 FROM $192

Piper Sandler has increased its target price for Texas Roadhouse Inc (TXRH.O) to $208 from $192. This news was reported by Reuters on August 10, 2026. The article states that this information reflects the author's opinion and is not intended as investment advice.

Wall Street Analysts Are Neutral on Top Healthcare Picks

Wall Street analysts have issued neutral ratings for Vertex Pharmaceuticals (VRTX) and Travere Therapeutics (TVTX), indicating that experts are neither bullish nor bearish on these healthcare stocks. Stifel Nicolaus analysts maintained Hold ratings for both companies, with specific price targets set. Despite these neutral …

Tungtex (Holdings) Co. Ltd. Revenue Breakdown – HKEX:518

Nutex Health Q2 Profit Soars As IDR Cost Reductions Drive Margin Gains

(RTTNews) - Shares of Nutex Health Inc. (NUTX) are up 14.88% today. The company recently reported its second-quarter 2026 financial results, with investors focusing on a sharp improvement in profitability, stronger hospital visit volumes, favorable IDR-related cost reductions and continued operating cash generation. Nutex …

Texas Roadhouse buys former Kaden Tower

Texas Roadhouse Inc., based in Louisville, has acquired the 16-story Kaden Tower, one of the city's distinctive office buildings. This purchase marks another significant investment by the restaurant chain in Louisville. The article, updated on August 10, 2026, details the transaction.

Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails

Vertex Pharmaceuticals (VRTX) stock rose 5.9% after a rival cystic fibrosis drug, SION-719 from Sionna Therapeutics, failed to meet its primary endpoint in a Phase 2a trial. This development solidifies Vertex's dominant position in the cystic fibrosis market. Despite the stock jump, Vertex's valuation …

Vertex Pharmaceuticals Jumps 6.7% After Truist Securities Maintains Buy

Vertex Pharmaceuticals (VRTX) saw its stock price jump 6.7% after five Wall Street firms either upgraded their ratings or increased price targets. The coordinated analyst action, with an average new price target of $554, indicates strengthening investor confidence in the biotechnology company. Investors are …

TEXAS INSTRUMENTS AKTIE: AI-Analysen, Prognose & Kursziel

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a …

Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise

Sionna Therapeutics' shares plummeted over 90% after its cystic fibrosis drug candidate, SION-719, failed a Phase 2a clinical trial. The failure of SION-719, intended as an add-on to Vertex Pharmaceuticals' Trikafta, reinforces Vertex's dominant position in the cystic fibrosis market, causing Vertex's shares to …

Texas Pacific Land Corporation (TPL) stock price, news, quote and history

This article provides a comprehensive overview of Texas Pacific Land Corporation (TPL), including its current stock price, recent performance, dividend information, and company profile. It details the company's involvement in land and resource management and water services within the Permian Basin, alongside financial highlights, …

Por que as ações da Vertex Pharmaceuticals disparam hoje? - Investing.com Brasil

Weekly Recap: Vertex $10B deal, guidance paused and Q2 loss — Crinetics

Crinetics Pharmaceuticals (CRNX) is being acquired by Vertex for approximately $10 billion. As a result, CRNX has paused its financial guidance despite reporting $25.1 million in Q2 2026 revenue and a $120.9 million net loss. Vertex, meanwhile, has raised its 2026 outlook and plans …

Vertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know

Vertex Pharmaceuticals Inc (VRTX) stock surged by 9.76% on August 10th following positive Phase 3 data for its non-opioid pain treatment and an upward revision of its full-year revenue guidance. The company outperformed its sector, attracting institutional capital and benefiting from a broader resurgence …

Vertex Pharmaceuticals stock hits all-time high at 539.99 USD

Vertex Pharmaceuticals Inc. (VRTX) stock reached an all-time high of $539.99, currently trading at $543.41, reflecting a 35% increase over the past year. Despite its strong performance and $125.7 billion market cap, an InvestingPro analysis suggests the stock might be overvalued relative to its …

Ação da Vertex Pharmaceuticals atinge máxima histórica de US$ 539,99 - Investing.com Brasil

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

Vardhman Polytex Reports Strong Profit on Land Sale; Debt Repaid

Is Texas Pacific Land (TPL) Overvalued, Or Is Its Price Justified?

Texas Pacific Land (TPL) has seen a strong 124.7% return over five years, but its current valuation suggests the stock is expensive. The company trades at a P/E ratio of 43.4x, significantly higher than the industry average, indicating it may be overvalued based on …

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Sionna Therapeutics announced that its experimental cystic fibrosis pill, SION-719, failed to show any additional benefit when used as an add-on therapy to Vertex Pharmaceuticals’ Trikafta in a Phase 2 trial. The company will discontinue the drug's development as an add-on and plans to …

Gretex Corporate Services allots 5.55 lakh warrants to promoter group

GE Appliances Expands Domestic Semiconductor Supply Chain With Texas Instruments

GE Appliances is expanding its domestic semiconductor supply chain by integrating Texas Instruments components into its next generation of connected laundry appliances. Starting in 2027, Texas Instruments will supply approximately one-third of the semiconductor chips for products manufactured at GE Appliances' new Louisville laundry …

Texas Roadhouse, Inc. acquired Wright Tower from In-Rel Properties, Inc. for $12 million.

Texas Roadhouse, Inc. (NasdaqGS:TXRH) has completed the acquisition of Wright Tower from In-Rel Properties, Inc. for $12 million. The transaction, paid in cash, was finalized on August 7, 2026. This acquisition involves a cash consideration of $12 million for the assets of Wright Tower.

Is Texas Pacific Land (TPL) Expensive On Earnings Or Are Data Center Plans Priced In?

Texas Pacific Land (TPL) reported strong Q2 2026 earnings with record revenue from royalties and water, alongside a strategic push into data center and power projects. Despite positive long-term momentum, the stock has seen a recent pullback. Analysts present mixed views on TPL's valuation, …

Oliver Luxxe Assets LLC Sells 13,446 Shares of Texas Capital Bancshares, Inc. $TCBI

Gretex Corporate Services Raises Capital via Preferential Allotment of Warrants to Promoter Group

Terex Corporation $TEX Position Lifted by Royal Bank of Canada

Contravisory Investment Management Inc. Takes Position in Textron Inc. $TXT

Contravisory Investment Management Inc. has acquired a new position in Textron Inc. (NYSE:TXT) by purchasing 12,511 shares valued at approximately $1.15 million. This move is part of broader institutional interest, with other major firms also adjusting their holdings in Textron. The company recently reported …

Deane Retirement Strategies Inc. Trims Holdings in Texas Instruments Incorporated $TXN

Deane Retirement Strategies Inc. significantly reduced its stake in Texas Instruments (TXN) by 67.5% in the second quarter, selling 18,080 shares and retaining 8,713 shares valued at $2.59 million. Despite this reduction, institutional investors collectively hold 84.99% of TXN's stock. Texas Instruments reported strong …